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Introduction
Peritoneal carcinomatosis (PC) is in strong context with 
morbidity and mortality in the management of several 
abdominal cancers, including colorectal, gastric, and ovarian 
cancers.1 Peritoneal seeding of cancer cells occurs in 10% to 
20% of such patients with tumor being examined for poten-
tially curative tumor resection.2 Because of the challenging 
treatment due to its relative resistance to systemic chemo-
therapy, PC has long been considered a terminal condition, 
and patients generally received palliative treatment.3 
However, treatment strategies have improved over the past 
few decades and resulted in a combined strategy of cytore-
ductive surgery (CRS) of all macroscopic intraperitoneal 
tumors with hyperthermic intraperitoneal chemotherapy 
(HIPEC). Today, this combined treatment (CRS and 
HIPEC) is increasingly accepted as a therapeutic option in 
some primary and secondary peritoneal malignancies.4 
Commonly used chemotherapeutic agents for HIPEC are 
mitomycin C (MMC) as well as oxaliplatin (OXA), the latter 
one with or without additional intravenous 5-fluorouracil 
(5-FU) treatment. Interestingly, in patients with PC from 
colorectal origin under such therapy, the 5-year overall sur-
vival rate was reported to range between 25% and 47%.5–7 As 
a consequence, an increasing number of tumor centers have 
been applying this combined therapeutic regimen.8–13
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Heat shock proteins (HSPs) are highly conserved proteins 
found in all prokaryotic and eukaryotic cells. Expression levels 
of HSPs rise in response to different environmental, physical, 
and chemical stress factors including cytotoxic agents and 
hyperthermic conditions. Heat shock proteins play a crucial 
role in chaperoning misfolded proteins and protecting cells 
from damage and apoptosis.14,15 They interact with many pro-
teins of cell signaling pathways that lead to reduced apoptosis 
and enhancement of cell migration, proliferation, and angio-
genesis.15–18 In addition, overexpression of HSPs has been 
shown to be associated with poor prognosis in many tumor 
entities.19,20 Previously, we reported that HSP expression in 
tumor tissues of patients with PC from different tumor enti-
ties was highly upregulated after HIPEC and that hyperther-
mic conditions resulted in increased HSP expression and 
resistance to hyperthermia-induced cell death in human 
HT-29 colon cancer cells.21 Here, we demonstrate the effects 
of hyperthermic chemotherapy on HSP expression profiles, 
tumor cell proliferation, and chemosensitivity in several estab-
lished human colon cancers using the well-established HIPEC 
protocols in humans.
Materials and Methods
Patients and human tissues
From a total of 63 patients who underwent CRS with addi-
tional HIPEC therapy as a closed procedure in our depart-
ment (October 2008 to April 2011) and available 
representative tumor tissues before and after HIPEC ther-
apy, 24 patients with isolated PC from colorectal cancer 
were investigated. Informed consent was obtained preopera-
tively, as was approved by the local medical ethics commit-
tee. Patient data are summarized in Table 1. The HIPEC 
therapy was performed under specific conditions (60 min-
utes permanent chemotherapeutical flux via external pump 
into the abdominal cavity after resection of relevant tumor 
masses with elevated temperature up to 41°C). Tumor biop-
sies from peritoneal tumors were taken before and after the 
HIPEC procedure. Tumor biopsies after a HIPEC proce-
dure were taken from specifically marked peritoneal areas 
with small peritoneal metastases completely resected after 
the HIPEC. The samples were immediately frozen in liquid 
nitrogen until further protein extraction. Samples for subse-
quent RNA extraction were stored in RNAlater (Qiagen, 
Hilden, Germany). For cryostat sections, samples were 
embedded in Tissue-Tek O.C.T. Compound (Sakura, 
Torrance, CA, USA).
Cell culture and in vitro HIPEC conditions
The human colon cancer cell lines HT-29, SW480, and 
SW620 were purchased from American Type Culture 
Collection (ATCC, Manassas, VA, USA) and cultured in 
RPMI 1640 medium (ATCC) supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin at 37°C in 5% 
CO2. To mimic HIPEC-like conditions, cancer cells were 
incubated for 60 minutes at different temperatures (37°C, 
41°C, and 43°C) including or without additional cytostatic 
treatment (5-FU: 11.5 µM, MMC: 25 µM, OXA: 150 µM) in 
a shaking water bath. Fresh normothermic medium without 
cytostatic agent was supplied afterward and cells were incu-
bated for 30 minutes, 24, 48, and 72 hours before analysis.
Immunofluorescence
Primary antibody against PCNA (proliferating cell nuclear 
antigen), HSP70, and Ki-67 were purchased from Abcam 
(Cambridge, UK); antibodies to HSP27 and HSP90 were 
obtained from Cell Signaling Technology (Danvers, MA, 
USA). Cy3 (indocarbocyanine) and fluorescein isothiocyanate 
conjugated secondary antibodies were obtained from Jackson 
ImmunoResearch (West Grove, PA, USA). The staining was 
performed on cryostat sections of snap frozen tumor specimen 
before and after HIPEC or on Cytospin specimen prepared 
24 hours after exposure to hyperthermic chemotherapy. For 
immune staining, samples were fixed in acetone and incubated 
with the primary antibody in Tris-buffered saline plus 0.5% 
bovine serum albumin overnight at 4°C in a humidified cham-
ber. Treatment with the secondary fluorochrome conjugated 
antibody was performed for 30 minutes at room temperature in 
a humidified chamber. Subsequently, slides were mounted with 
DAPI Fluoromount-G (Southern Biotech, Birmingham, AL, 
USA) and analyzed using an Olympus BX51 Microscope and 
the cellSens Dimension software (Hamburg, Germany).
RNA extraction and quantitative real-time 
polymerase chain reaction
Gene expression of HSPB1 (HSP27-1), HSPA1A and 
HSPA1B (HSP70 1A and 1B), HSP90AA1 and HSP90AA2 
(HSP90α A1 and A2) as well as proliferation markers PCNA 
and Ki-67 was determined using quantitative real-time poly-
merase chain reaction (PCR). Total cellular RNA was extracted 
using RNeasy Mini Kit (Qiagen) on the QIAcube platform 
(Qiagen) according to the manufacturer’s instructions. Reverse 
transcription was performed using ImProm II Reverse 
Transcriptase System (Promega, Mannheim, Germany) and 
Eppendorf Mastercycler (Eppendorf, Hamburg, Germany). 
Gene quantification was performed using RT2 qPCR Primer 
Assays (Qiagen) and MESA GREEN qPCR MasterMix 
(Eurogentec Deutschland GmbH, Koeln, Germany) accord-
ing to the manufacturer’s protocol. Housekeeping genes 
β-actin and TBP (TATA-binding protein) were used for rela-
tive quantification. All PCR reactions were conducted in 
duplicates on a Biorad CFX96 Touch Real-Time PCR 
Detection System. Reproducibility was confirmed by 3 inde-
pendent PCR runs. The relative gene expression value, fold 
difference (FD), is expressed as 2−ΔΔCq.
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Western blot
Protein extracts from tumor tissue samples and colon cancer 
cell lines were performed using lysis buffer radioimmunopre-
cipitation assay (RIPA)-containing 1,1,1-Trichloro-2,2-bis(4-
chlorophenyl)ethane (DDT; Sigma-Aldrich, Steinheim, 
Germany) and protease/phosphatase inhibitor cocktails 
(Merck Millipore, Billerica, MA, USA). Tumor tissue samples 
before and after a HIPEC were cut in small pieces and homog-
enized for 10 minutes in lysis buffer using TissueLyser (Qiagen) 
before incubation on a rotator at 4°C for 30 minutes and subse-
quent centrifugation (full speed, 4°C, 20 minutes). The super-
natant was collected and stored at −80°C. For preparation of 
cell lysates, adherent cells were detached using Accutase solu-
tion (Sigma-Aldrich) and pelleted at 300×g for 10 minutes. 
After resuspension in RIPA lysis buffer, cells were incubated 
on a rotator at 4°C for 30 minutes, then centrifuged (full speed, 
4°C, 20 minutes), and supernatant was collected and stored at 
−80°C. Protein concentrations were determined by Bradford 
assay using Roti-Quant solution (Carl Roth, Karlsruhe, 
Germany). For sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis, NuPAGE SDS Buffer and NuPAGE Novex Mini 
Gels (Thermo Fisher Scientific) were used according to the 
manufacturer’s instructions. Western blotting on nitrocellulose 
was performed using iBlot Dry Blotting System and iBlot Gel 
Transfer Stacks (Thermo Fisher Scientific) according to the 
manufacturer’s protocol. Blots were probed with antibodies to 
HSP27, HSP70, HSP90, β-actin, Bcl-xL, and PCNA. 
Antibodies to HSP70 and Bcl-xL were obtained from Abcam. 
HSP27, HSP90, PCNA, and β-actin antibodies were 
Table 1. Patients with PC from colorectal cancer assigned to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
GEnDER AGE UICC PTnM GRADInG PRIMARy/
SECOnDARy PC
FOllOW-UP, MO AlIVE/DEATh
Male 65 III T4n0M0 3 S 26 D
44 III T4an2bM0 3 S 36 A
53 III T4n1M0 2 S 39 A
74 III T4n1M0 2 S 26 D
80 III T4bn1bM0 2 S 11 A
49 IV T4an1aM1 2 P 25 D
44 IV T3n2M1b 3 P 36 A
49 IV T4an1bM1b 2 P 40 A
56 IV T4n1bM1b 2 P 18 D
59 IV T3n2bM1b 3 P 28 D
67 IV T4bn2M1b 2 P 32 D
Female 58 II T3n0M0 3 S 48 A
62 III T4bn1aM0 2 S 46 A
56 III T2n2bM0 2 S 48 A
38 III T4an1aM0 2 S 60 A
37 III T3n1bM0 2 S 36 A
77 III T4n1M0 2 S 15 A
59 III T4an1M0 3 S 19 A
59 IV T3n0M1 2 P 20 D
50 IV T3n1cM1b 3 P 23 D
56 IV T4an2aM1b 3 P 31 D
41 IV T3n2bM1 3 S 6 D
41 IV T3n2aM1b 2 P 25 A
73 IV T4an2bM1b 3 P 30 A
Abbreviations: PC, peritoneal carcinomatosis; UICC, Union for International Cancer Control.
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purchased at Cell Signaling Technology. Anti-mouse IgG and 
anti-rabbit IgG horseradish peroxidase (HRP)-conjugated 
secondary antibodies were obtained from Santa Cruz 
Biotechnology (Dallas, TX, USA). Quantification was per-
formed using ImageJ software: relative optical density (ROD) 
was expressed as values for proteins of interest in relation to 
values of β-actin loading controls.
MTS proliferation and chemosensitivity assay
To investigate the effect of hyperthermia on tumor cell prolif-
eration and chemoresistance, 4000 cells/well (HT-29) or 
8000 cells/well (SW480, SW620) were seeded in 96 well plates 
and preincubated for 3 days. To mimic HIPEC-like conditions, 
cells were treated as described previously. Cell viability was 
measured using CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega, Mannheim, Germany) accord-
ing to the manufacturer’s instructions.
HSP inhibition assay
As described previously, 4000 cells/well (HT-29) or 8000 cells/
well (SW480, SW620) were seeded in 96-well plates and pre-
incubated for 3 days. The HIPEC-like conditions were then 
applied as defined above. Immediately after exposure to hyper-
thermic chemotherapy, cells were treated with a combination 
of HSP90 and HSP70 inhibitors, as single HSP90 inhibition 
is known to induce the activation of the heat shock response, a 
cell survival mechanism that induces overexpression of 
HSP7070 and other HSPs.22 About 500 mM 17-AAG 
(HSP90 inhibitor; Santa Cruz Biotechnology) and 10 µM 
VER155008 (HSP70 inhibitor) were applied and cell viability 
was measured 24 hours after exposure as described before.
Results
Western blot analysis of HSP27, HSP70, and 
HSP90 after hyperthermic chemotherapy
HSP27, HSP70, and HSP90 Western blot analysis was per-
formed in 3 human colon cancer cell lines (HT-29, SW480, 
and SW620) 24, 48, and 72 hours after exposure to hyperther-
mia with or without additional chemotherapy using 5-FU, 
MMC, and OXA. Representative Western blots of this detailed 
protein analysis are demonstrated in Figures 1 to 3.
In SW480 colon cancer cells, increased HSP27 protein expres-
sion was observed 1, 2, and 3 days after initial hyperthermia 
(60 minutes) compared with normothermic controls (41°C and 
43°C versus 37°C) (Figure 1A). Additional exposure to 5-FU 
caused further increase in HSP27 protein expression at all investi-
gated time points (Figure 1A). Similar HSP27 expression profiles 
were obtained in HT-29 and SW620 colon cancer cells 
(Supplementary Figure S1A). Although 24 hours after incubation 
with or without MMC no relevant changes in HSP27 expression 
were detected in HT-29 cells, upregulated expression as in SW480 
for 5-FU tumor cells was demonstrated after 48 and 72 hours: 
hyperthermia alone resulted in intense HSP27 expression com-
pared with normothermic controls and additional exposure to 
MMC caused further increase in expression (Figure 2A). SW620 
cancer cells showed upregulated HSP27 expression 24 hours after 
treatment with hyperthermia alone, whereas additional chemo-
therapy with OXA led to increased protein expression even after 
72 hours (Figure 3A). Similar effects of chemotherapy were also 
detected in HT-29 (OXA) and SW620 and SW480 colon cancer 
cells, respectively (MMC: Supplementary Figure S1B and OXA: 
Supplementary Figure S1C).
Although HSP27 expression was detected at moderate 
basal levels and was strongly inducible through hyperthermia 
and/or cytostatic treatment, intense HSP70 and HSP90 base-
line expression was already observed in all investigated normo-
thermic controls (HT-29, SW480, and SW620 colon cancer 
cells). Further increase in HSP70 expression after hyperther-
mic chemotherapy was demonstrated in tumor cells exposed to 
5-FU, MMC, and OXA (Figures 1B, 2B, and 3B), whereas 
HSP90 expression was found elevated only after treatment 
with 5-FU and MMC (Figures 1C and 2C).
To additionally visualize HSP expression increase after 
exposure to chemotherapy, representative examples of immu-
nofluorescent stainings in SW480 cells treated with 5-FU at 
normothermia (37°C) and hyperthermia (41°C and 43°C) are 
demonstrated in Figure 8 (red fluorescence).
HSP gene expression profiles after hyperthermic 
chemotherapy
Based on the results of the Western blot analysis, the induc-
tion of HSP27, HSP70, and HSP90 messenger RNA 
(mRNA) expression was further analyzed using 2 different 
isoforms for both HSP70 and HSP90 (HSPA1A: HSP70 1A 
and HSPA1B: HSP70 1B; HSP90AAA1: HSP90α A1 and 
HSP90AA2: HSP90α A2).
HSP70 expression was significantly increased in SW480 
colon cancer cells early after exposure to hyperthermia and par-
ticularly after profound hyperthermia of 43°C (HSP70 1A 
[HSPA1A] at 0.5 hours: 41°C = FD 2.7, 43°C = FD 30.0 versus 
normothermic control = FD 1) (Figure 4A, top). Additional 
chemotherapy with 5-FU resulted in further increased gene 
expression (41°C = FD 12.6 and 43°C = FD 38). After 24, 48, 
and 72 hours, significantly upregulated HSP70 1A [HSPA1A] 
mRNA expression levels were observed in 5-FU–treated can-
cer cells at all investigated temperatures (37°C: FD 2.2, FD 2.9, 
and FD 2.5; 41°C: FD 1.9, FD 3.0, and FD 1.9; 43°C: FD 2.1, 
FD 3.7, and FD 3.7, respectively) (Figure 4A, top). Comparable 
results of upregulated HSP70 expression were found after 
exposure to MMC at the initial time point (0.5 hours), although 
expression returned to control levels later on (Figure 4A, 
center). When exposed to OXA, significantly increased HSP70 
1A [HSPA1A] gene expression was demonstrated again at the 
initial time point (0.5 hours: FD 43.9) as well as the next inter-
val (24 hours: FD 2.4) in SW480 cancer cells. However, no 
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gene expression changes were observed at later time points 
(Figure 4A, bottom). HT-29 and SW620 colon cancer cells 
treated with chemotherapy demonstrated comparable effects 
on HSP70 1A [HSPA1A] (5-FU and MMC: Supplementary 
Figure S2A and 5-FU, MMC, and OXA: Supplementary 
Figure S2B). In accordance with these results, comparable 
findings were obtained for HSP70 1B [HSPA1B] (representa-
tive example in SW480 cells: Supplementary Figure S3A).
HSP90α A1 [HSP90AA1] gene expression was found 
to be significantly increased in SW480 cells at investigated 
initial high temperatures (41°C and 43°C) and time points 
when treated with 5-FU and compared with normothermic 
controls and cells without chemotherapy (Figure 4B, top). 
Early after hyperthermic incubation at 43°C with 5-FU 
(0.5 hours), tumor cells showed a 3-fold increased gene 
expression. After 24, 48, and 72 hours, 5-FU–treated colon 
Figure 1. Western blot analysis of (A) hSP27, (B) hSP70, and (C) hSP90 in SW480 cells 24, 48, and 72 hours after treatment (60 minutes) with 
hyperthermia including or without additional chemotherapy using 5-fluorouracil (5-FU).
β-actin probe was used as a control for protein loading. Relative optical density was determined using ImageJ software: values for proteins of interest were calculated in 
relation to values of loading controls. normothermic cells (37°C control) were standardized to baseline.
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cancer cells again demonstrated significantly upregulated 
mRNA expression when incubated under normothermic 
and hyperthermic conditions (37°C: FD 1.9, FD 3.4, and 
FD 1.8, respectively; 41°C: FD 2.1, FD 4.0, and FD 2.0, 
respectively; and 43°C: FD 2.2, FD 4.6, and FD 3.4, respec-
tively) (Figure 4B, top). Interestingly, when compared with 
results after 24 hours, cells exposed to 5-FU at 43°C showed 
highest mRNA expression at all time points. In cancer cells 
treated with MMC, again significantly increased HSP90α 
A1 [HSP90AA1] expression profiles were detected at 43°C 
(24 hours: FD 1.7, 48 hours: FD 1.4, and 72 hours: FD 1.4) 
as well as both hyperthermic temperatures (41°C = 48 hours: 
FD 1.4, 72 hours: FD 1.5; 43°C = 24 hours: FD 1.5, 72 hours: 
FD 2.6) (Figure 4B, center), whereas SW480 cells treated 
with OXA showed upregulated expression after normo-
thermic incubation (24 hours: FD 1.6, 48 hours: FD 1.2, 
Figure 2. Western blot analysis of (A) hSP27, (B) hSP70, and (C) hSP90 in hT-29 cells 24, 48, and 72 hours after treatment (60 minutes) with 
hyperthermia including or without additional chemotherapy using mitomycin C (MMC).
β-actin probe was used as a control for protein loading. Relative optical density was determined using ImageJ software: values for proteins of interest were calculated in 
relation to values of loading controls. normothermic cells (37°C control) were standardized to baseline.
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72 hours: FD 2.0) and hyperthermic condition at 41°C 
(24 hours: FD 1.4, 48 hours: FD 2.4, 72 hours: FD 1.3) 
(Figure 4B, bottom). Comparable results were obtained in 
colon cancer cell lines HT-29 and SW620 (Supplementary 
Figure S4A and S4B). In addition, representative compara-
ble results of expression analysis of HSP90α A2 
[HSP90AA2] in SW620 colon cancer cells are demon-
strated in Supplementary Figure S3B.
Next to HSP70 and HSP90 gene expression, the profiles of 
HSP27 (HSP27-1, HSPB1) were analyzed. HSP27 was signifi-
cantly overexpressed in HT-29 colon cancer cells early after expo-
sure to hyperthermic chemotherapy with 5-FU compared with 
normothermic controls and tumor cells without chemotherapy 
(0.5 hours after 41°C: FD 3.8 and 43°C: FD 11.7 versus controls 
without cytostatic treatment 41°C: FD 1.5 and 43°C: FD 1.5) 
(Figure 5, top). No changes in HSP27 gene expression were 
Figure 3. Western blot analysis of (A) hSP27, (B) hSP70, and (C) hSP90 in SW620 cells 24, 48, and 72 hours after treatment (60 minutes) with 
hyperthermia including or without additional chemotherapy using oxaliplatin (OXA).
β-actin probe was used as a control for protein loading. Relative optical density was determined using ImageJ software: values for proteins of interest were calculated in 
relation to values of loading controls. normothermic cells (37°C control) were standardized to baseline.
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detected 24 hours after hyperthermic chemotherapy, whereas 48 
and 72 hours after incubation, significantly upregulated expression 
was again observed in HT-29 cancer cells treated with 5-FU at 
normothermic and hyperthermic conditions (37°C: FD 5.3 and 
FD 2.6, 41°C: FD 6.6 and FD 4.4, and 43°C: FD 5.3 and FD 5.7, 
respectively) (Figure 5, top). When incubated with MMC, signifi-
cantly elevated HSP27 expression was again observed under nor-
mothermic and hyperthermic conditions 24 and 48 hours after 
exposure (37°C: FD 2.3 and FD 4.3, 41°C: FD 2.1 and FD 4.1, 
and 43°C: FD 1.8 and FD 5.0, respectively) (Figure 5, center). 
When treated with OXA, again significantly upregulated expres-
sion was demonstrated at 24, 48, and 72 hours (37°C: FD 4.4 and 
FD 2.5, 41°C: FD 3.0, and 43°C: FD 2.1, FD 2.0, and FD 3.6, 
respectively) (Figure 5, bottom). Next to HT-29, SW480, and 
SW620 colon cancer cells treated with chemotherapy 
demonstrated comparable effects (5-FU: Supplementary Figure 
S5A and 5-FU and MMC: Supplementary Figure S5B).
A comprehensive overview of the HSP gene expression 
changes in HT-29 colon cancer cells is given in Table 2 to allow 
for comparison of heat stress–induced and chemotherapy-
induced HSP upregulation and for differentiation on the back-
ground of the 3 commonly used cytotoxic agents and temperatures. 
This demonstrates highly upregulated HSPs very early after 
hyperthermic but not normothermic chemotherapy (>2-fold, 
Table 2) (0.5 hours after treatment, Table 2). After 48 and 
72 hours of initial treatment with cytostatic and chemotoxic sub-
stances, tumor cells showed upregulated HSP expression profiles 
(>2-fold), which were mostly independent of initially used nor-
mothermic or hyperthermic conditions. This suggests rather 
chemotoxicity-induced intracellular stress mechanisms over time 
Figure 4. (A) Gene expression analysis (real-time polymerase chain reaction) of hSPA1A (hSP70 1A) and (B) hSP90AA1 (hSP90α 1A), in SW480 cells 
0.5, 24, 48, and 72 hours after treatment (60 minutes) with hyperthermia including or without additional chemotherapy (CTx) using 5-fluorouracil (5-FU), 
mitomycin C (MMC), or oxaliplatin (OXA).
normothermic cells without cytostatic treatment (37°C control) were standardized to baseline. The relative gene expression is expressed as 2−ΔΔCq (= fold difference, FD). 
Reproducibility was confirmed by 3 independent runs. *P < .05; **P < .0005; ***P < .0001 (Student t test).
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than hyperthermia-mediated molecular changes. Comparing the 
used cytostatic/cytotoxic agents, treatment with 5-FU interest-
ingly resulted in most distinct mRNA upregulation in all investi-
gated HSPs and at most time points, whereas MMC showed 
moderate influence on HSP induction over time (Table 2). 
Differences between the used cytostatic agents may occur due to 
their different modes of action. While 5-FU is incorporated in 
DNA and RNA thus inhibiting transcription and translation, 
MMC serves as a prototype for drugs with bioreductive alkyla-
tion and OXA binds to DNA bases, thus leading to cross-linking 
of and inhibiting DNA synthesis and transcription.23–25
Effects of hyperthermic chemotherapy on tumor cell 
proliferation
To dissect the effects of hyperthermia and hyperthermic chemo-
therapy on tumor cell growth, MTS proliferation assays were per-
formed. HT-29 cancer cells showed decreased cell viability 
24 hours after isolated hyperthermic treatment compared with 
tumor cells incubated under normothermic condition (41°C: 88% 
and 43°C: 91% versus 37°C: 100%, each P < .05), whereas 48 hours 
after hyperthermic incubation, significantly elevated cell viability 
was observed (43°C: 115%, P < .005) suggesting a rebound effect 
in cell proliferation (Figure 6A). After 3 days of exposure to 
hyperthermia, cell viability returned to normal (Figure 6A).
Interestingly, HT-29 tumor cells that were incubated with 
5-FU under hyperthermic condition showed increased cell viabil-
ity compared with normothermic incubation with 5-FU (48 hours 
after treatment at 41°C: 78%, and 43°C: 81%, versus 37°C: 66%, 
P < .05 and P < .005, respectively, and after 72 hours at 43°C: 56% 
versus 37°C: 49%, P < .05) (Figure 6B). Hyperthermic incubation 
with MMC demonstrated comparable results: cell viability of sur-
viving HT-29 cells at lower level when compared with 5-FU 
treatment was significantly increased after 48 hours (43°C: 54% 
versus 37°C: 48%, P < .05) and after 72 hours (41°C: 37% and 
43°C: 32% versus 37°C: 27%, P < .0001 and P < .05, respectively) 
(Figure 6C). Moreover, treatment with OXA under hyperthermic 
condition again resulted in increased cell viability 48 hours after 
initial incubation with the drug (41°C: 79% and 43°C: 81% versus 
37°C: 71%, each P < .05) (Figure 6D). Hyperthermic treatment of 
SW480 colon cancer cells with 5-FU, MMC, and OXA demon-
strated comparable results 24 hours after drug exposure and thus 
confirmed the observation of increased cell viability of surviving 
cancer cells (Supplementary Figure S6).
Effects of HSP inhibition after hyperthermic 
chemotherapy
To analyze the potential benefit of additional HSP inhibition, 
a combination of HSP90 (17-AAG) and HSP70 (VER155008) 
was applied to HT-29 cancer cells after exposure to hyper-
thermic chemotherapy at 43°C. Colon cancer cells exposed to 
simultaneous HSP90/HSP70 inhibition demonstrated sig-
nificantly decreased cell viability compared with samples 
without inhibitors in control cells and tumor cells pretreated 
with 5-FU, OXA, or MMC (control cells: 83% versus 100%, 
P < .05; 5-FU: 97% versus 77%, P < .005; OXA: 79% versus 
66%, P < .05; MMC: 59% versus 48%, P < .05) (Figure 6E). 
Figure 5. Gene expression analysis (real-time polymerase chain 
reaction) of hSPB1 (hSP27 1) in hT-29 cells 0.5, 24, 48, and 72 hours 
after treatment (60 minutes) with hyperthermia including or without 
additional chemotherapy (CTx) using 5-fluorouracil (5-FU), mitomycin C 
(MMC), or oxaliplatin (OXA).
normothermic cells without cytostatic treatment (37°C control) were 
standardized to baseline. The relative gene expression is expressed as 2−ΔΔCq 
(= fold difference, FD). Reproducibility was confirmed by 3 independent runs. 
*P < .05; **P < .0005; ***P < .0001 (Student t test).
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Interestingly, when comparing HSP inhibitor–treated control 
cells with HT-29 cells additionally pretreated with 5-FU, 
OXA, or MMC, cell viability was significantly reduced in cells 
previously exposed to cytostatic agents (5-FU: 83% versus 
77%, P < .05; OXA: 83% versus 66%, P < .0001; MMC: 83% 
versus 48%, P < .0001) (Figure 6E).
Cellular expression of proliferation markers after 
hyperthermic chemotherapy
Next to cell viability, chemotoxic and heat stress–mediated 
effects on expression of proliferation markers PCNA and 
Ki-67 were investigated.
Rapidly upregulated PCNA gene expression after hyper-
thermic chemotherapy with 5-FU was observed in HT-29 
cancer cells, whereas no changes were visible after normo-
thermic incubation with the substance (0.5 hours after treat-
ment at 41°C: FD 9.8 and 43°C: FD 19.4) (Figure 7A, top). 
After 48 and 72 hours, cancer cells showed again elevated 
PCNA gene expression (41°C: FD 2.5 and FD 4.3, 43°C: 
FD 2.5 and FD 4.1, respectively). Upregulated PCNA gene 
expression was also detected in tumor cells incubated with 
5-FU chemotherapy under normothermic condition 
(72 hours at 37°C: FD 4.6) (Figure 7A, top). Hyperthermic 
chemotherapy using MMC resulted in increased PCNA 
expression 24 and 48 hours after incubation (41°C: FD 2.6 
and FD 5.3, 43°C: FD 2.7 and FD 3.7, respectively), whereas 
normothermic chemotherapy with MMC caused elevated 
PCNA expression after 24, 48, and 72 hours (FD 2.6, FD 
3.1, and FD 2.1, respectively) (Figure 7A, center). In HT-29 
cells treated with OXA, moderately increased PCNA gene 
expression was observed after 48 hours (41°C: FD 1.9 and 
43°C: FD 1.7) and after 72 hours (37°C: FD 1.9, 41°C: FD 
2.0, and 43°C: FD 3.0) (Figure 7A, bottom).
Next to PCNA, Ki-67 expression was analyzed as second 
proliferation marker. After 24 hours and more vigorously after 
48 hours of initial normothermic and hyperthermic incubation 
with all 3 cytotoxic substances, HT-29 tumor cells demon-
strated significantly upregulated Ki-67 expression (5-FU 
37°C: FD 4.2 and 8.0, 41°C: FD 4.5 and 11.8, and 43°C: FD 
3.6 and 11.1, respectively; MMC 37°C: FD 3.4 and 7.2, 41°C: 
FD 8.6 and 7.5, and 43°C: FD 5.4 and 6.9, respectively; OXA 
37°C: FD 3.3 and 5.1, 41°C: FD 2.2 and FD 4.1, and 43°C: 
FD 2.1 and 4.2, respectively (Figure 7B)). Comparable results 
for PCNA (exception: OXA) and Ki-67 gene expression were 
obtained in SW480 (Supplementary Figure S7) and SW620 
(Supplementary Figure S8) colon cancer cells.
To additionally visualize PCNA and Ki-67 expression 
increase after exposure to chemotherapy, representative exam-
ples of immunofluorescent stainings in SW480 cells treated 
with 5-FU at normothermia (37°C) and hyperthermia (41°C 
and 43°C) are demonstrated in Figure 8 (green fluorescence).
For PCNA, additional Western blot analysis was performed. In 
HT-29 cancer cells, 5-FU chemotherapy under normothermic 
condition resulted in moderately increased protein expression at 
all investigated time points (Figure 9A). Hyperthermic 5-FU 
Table 2. hSP gene expression in hT-29 colon cancer cells after treatment with normothermic and hyperthermic chemotherapy.
COnDITIOnS TIME, h hSP70 1A (hSPA1A) hSP90A IA (hSP9OAA1) hSP27-1 (hSPB1)
5-FU MMC OXA 5-FU MMC OXA 5-FU MMC OXA
37°C + CTx 0.5 − − + − − + − − −
41°C + CTx 0.5 ++++ +++ + ++ ++ − ++ + −
43°C + CTx 0.5 +++++ +++ +++ ++ ++ − +++ + +
37°C + CTx 24 + + + + + + + ++ +
41°C + CTx 24 − + − + + + + ++ +
43°C + CTx 24 + + + ++ + + + + +
37°C + CTx 48 + − ++ ++ + ++ +++ ++ ++
41°C + CTx 48 + + − ++ ++ + +++ ++ +
43°C + CTx 48 ++ − + ++ + + +++ ++ +
37°C + CTx 72 ++ − + ++ + + ++ + ++
41°C + CTx 72 ++ − ++ ++ − + ++ + ++
43°C + CTx 72 ++ − + +++ − + +++ + ++
Abbreviations: 5-FU, 5-fluorouracil; CTx chemotherapy; hSP, heat shock protein; MMC, mitomycin C; OXA, oxaliplatin.
hSP gene expression (quantitative real-time PCR) after treatment (60 minutes) with hyperthermia including or without additional CTx using 5-FU, MMC, or OXA. 
normothermic cells (37°C) were standardized to baseline (= 1). Gene expression is as follows: − <1-fold, + >1-fold, ++ >2-fold, +++ >5-fold, ++++ >15-fold, and +++++ 
>30-fold difference.
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chemotherapy resulted in increased protein expression after expo-
sure to 41°C and 43°C (ROD = 307% and ROD = 191%, respec-
tively) compared with normothermic controls and corresponding 
cancer cells without 5-FU chemotherapy (Figure 9A). 
Normothermic and hyperthermic treatment with MMC 
comparably induced PCNA expression at all investigated time 
points (Figure 9B). HT-29 tumor cells treated with OXA again 
demonstrated increased PCNA expression (Figure 9C). In accord-
ance with these observations, comparable results were obtained in 
SW480 and SW620 colon cancer (Supplementary Figure S9).
Figure 6. (A) MTS proliferation assay of hT-29 colon cancer cells 24, 48, and 72 hours after single hyperthermic treatment (60 minutes) or (B) additional 
chemotherapy (CTx) during hyperthermic intraperitoneal chemotherapy–like conditions using 5-fluorouracil (5-FU), (C) mitomycin C (MMC), or (D) 
oxaliplatin (OXA). (E) MTS proliferation assay of hT-29 colon cancer cells 24 hours after hyperthermic chemotherapy (43°C) including or without additional 
combined hSP70/90 inhibition using 17-AAG (hSP90) and VER155008 (hSP70).
Colon cancer cells under normothermic condition (A, 37°C control), colon cancer cells without cytostatic treatment (B-D, control), and colon cancer cells without 
exposure to cytostatic agents and hSP inhibitors (E, control), respectively, were standardized to baseline. *P < .05; **P < .0005; ***P < .0001 (Student t test).
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Antiapoptotic protein analysis after hyperthermic 
chemotherapy
To investigate the influence of hyperthermic chemotherapy on 
tumor cell apoptosis, protein expression of antiapoptotic Bcl-xL 
was further analyzed. As demonstrated in HT-29 cancer cells, 
initial treatment with 5-FU under normothermic and hyper-
thermic condition resulted in moderate Bcl-xL increase at all 
investigated time points (Figure 10A). Mitomycin C as well as 
OXA treatment also caused an induction of Bcl-xL expression 
after 24, 48, and 72 hours (Figure 7B and 7C).
Bcl-xL and PCNA analysis after hyperthermic 
chemotherapy in patient tumors from PC of 
colorectal cancer origin
For Bcl-xL and PCNA, additional Western blot analysis was 
performed in tumors from 22 patients with PC undergoing a 
Figure 7. Gene expression analysis (real-time polymerase chain reaction) of proliferation markers (A) PCnA (proliferating cell nuclear antigen and (B) 
Ki-67 in hT-29 cells 0.5, 24, 48, and 72 hours after treatment (60 minutes) with hyperthermia including or without additional chemotherapy (CTx) using 
5-fluorouracil (5-FU), mitomycin C (MMC), or oxaliplatin (OXA).
Colon cancer cells under normothermic condition without cytostatic treatment (37°C control) were standardized to baseline. The relative gene expression is expressed as 
2−ΔΔCq (= fold difference, FD). Reproducibility was confirmed by 3 independent runs. *P < .05; **P < .0005; ***P < .0001 (Student t test).
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HIPEC procedure with MMC or OXA combined or without 
systemic 5-FU. After Western blot analysis, 7 of 22 patient 
tumor specimens had to be excluded from further analysis due to 
pronounced protein degradation in samples after HIPEC. 
Peritoneal tumors showed an increased expression for both 
Bcl-xL (n = 6/8, 75%, ROD = 190%, ROD = 218%, ROD = 228%, 
ROD = 269%, ROD = 119%, and ROD = 110%) and PCNA 
(n = 4/8, 50%, ROD = 187%, ROD = 146%, ROD = 228%, and 
ROD = 239%) (Figure 11A).
In addition, increased PCNA expression after a HIPEC 
procedure was demonstrated in the tumors using immunofluo-
rescent techniques for the peritoneal tumors (Figure 11B).
Discussion
Today, the combined treatment of CRS with HIPEC repre-
sents a promising therapeutic strategy in several peritoneal 
malignancies.4 Recent clinical data point to beneficial effects in 
selected patients with isolated PC and indication for this 
procedure. For patients with PC from colorectal cancer, 
HIPEC was recently reported to be associated with improved 
overall survival and disease-free survival.6,26,27 These reports 
were mostly from matched case control studies from single 
centers and protocols comprised the chemotherapeutic sub-
stances MMC and OXA that were given at high dosages locally 
into the abdomen for either 30 or 60 minutes. Hyperthermic 
conditions in the abdomen ranged between 41°C and 43°C. 
However, these protocols were mostly defined on empirical 
data. Thus, further (pre)clinical data may improve hyperther-
mic effects when combined with the currently used chemo-
therapeutic substances in the clinic. Combined hyperthermia 
with high-dose local chemotherapy has most recently been 
demonstrated to exert beneficial effects in several settings.28 
One of the obvious mechanisms described to be responsible is 
an increase in the drug concentration in the peritoneal tissue as 
has been demonstrated in a murine model analyzing the effects 
of heat on 3 different doses of intraperitoneal OXA (460, 920, 
Figure 8. Immunofluorescent stainings of PCnA (green), Ki-67 (green), hSP27 (red), hSP70 (red), and hSP90 (red).
FITC (fluorescein isothiocyanate), green; Cy3 (indocarbocyanine), red; DAPI (4′,6-diamidino-2-phenylindole dihydrochloride); blue—nuclear counterstaining.
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and 1840 mg/mL) at 3 different perfusion temperatures (37°C, 
40°C, and 43°C).29 In addition, varying effects of hyperthermia 
considering perfusion and oxygenation have been detected in 
cancerous and normal tissue. Although perfusion is increased 
by hyperthermia in normal tissue, opposite observations were 
made in tumor tissues with reduced perfusion leading to 
hypoxia in the tumor cells.30 Moreover, functional proteins 
within the tumor cells become unfolded, and the cell 
membrane, nuclear DNA, cytoskeleton, and cell organelles can 
be damaged.31 Heat shock proteins are likely to play a signifi-
cant role in this process as highly conserved proteins induced in 
response to different environmental, physical, and chemical 
stress factors such as cytotoxic agents and hyperthermic condi-
tions. They act as a defense mechanism toward apoptosis-
inducing events. Heat shock proteins are known to play a 
crucial role in chaperoning misfolded proteins and protecting 
Figure 9. Western blot analysis of PCnA (proliferating cell nuclear antigen) in hT-29 cells 24, 48, and 72 hours after treatment (60 minutes) with (A) 
hyperthermia including or without additional chemotherapy using (B) 5-fluorouracil (5-FU), mitomycin C (MMC), or (C) oxaliplatin (OXA).
β-actin probe was used as a control for protein loading. Relative optical density was determined using ImageJ software: values for proteins of interest were calculated in 
relation to values of loading controls. normothermic cells without cytostatic treatment (37°C control) were standardized to baseline.
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cells from damage and overexpression of HSPs in various 
tumor entities in association with poor prognosis.14,15,19,20 
Previously, we demonstrated upregulated HSP27, HSP70, and 
HSP90 mRNA and protein expression in tumors from PC of 
different entities after clinical HIPEC procedures. These 
observations were confirmed in in vitro studies analyzing colon 
cancer cells exposed to hyperthermia early after treatment 
(30 minutes and 12 hours).21
Here, we demonstrated for the first time that colon cancer 
cells exposed to cytostatic treatment with chemotherapeutic 
substances for HIPEC (MMC and OXA) and for systemic 
chemotherapy (5-FU) are highly sensitive for upregulated 
expression of all 3 HSPs, HSP27, HSP70 and HSP90, when 
imitating clinically HIPEC conditions. Cytostatic treatment 
for 1 hour using 5-FU, MMC, or OXA under hyperthermia 
resulted in significantly increased gene expression of 
Figure 10. Western blot analysis of antiapoptotic Bcl-xl in hT-29 cells 24, 48, and 72 hours after treatment (60 minutes) with hyperthermia including or 
without additional chemotherapy using (A) 5-fluorouracil (5-FU), (B) mitomycin C (MMC), or (C) oxaliplatin (OXA).
β-actin probe was used as a control for protein loading. Relative optical density was determined using ImageJ software: values for proteins of interest were calculated in 
relation to values of loading controls. normothermic cells without cytostatic treatment (37°C control) were standardized to baseline.
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investigated HSPs (HSP27, HSP70, and HSP90) compared 
with normothermic conditions (37°C) as well as corresponding 
hyperthermic conditions alone without chemotherapy. Even 
3 days after exposure, increased HSP expression profiles were 
observed suggesting similar effects in vivo after a HIPEC 
procedure. This may occur particularly in those residual tumor 
cells from peritoneal surface areas of a patient with local hypoxia. 
Moreover, hyperthermic chemotherapy resulted in distinct 
upregulation of HSP expression combined with constitutively 
overexpressed HSP70 and HSP90 in the investigated colon 
Figure 11. (A) Western blot analysis of antiapoptotic Bcl-xl and proliferation marker PCnA (proliferating cell nuclear antigen) in tumor tissue samples 
from peritoneal carcinomatosis of patients with colorectal cancer before (pre) and after (post) hIPEC. (B) Immunofluorescent staining of PCnA in 
peritoneal tumor tissue samples before (pre) and after (post) hIPEC. Cy3 (indocarbocyanine), red; DAPI (4′,6-diamidino-2-phenylindole dihydrochloride), 
blue—nuclear counterstaining. hIPEC indicates hyperthermic intraperitoneal chemotherapy.
β-actin probe was used as a control for protein loading. Relative optical density was determined using ImageJ software: values for proteins of interest were calculated in 
relation to values of loading controls. Pre-hIPEC samples were standardized to baseline.
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cancer cells. Although HSP27 expression was detected at mod-
erate basal levels, intense HSP70 and HSP90 baseline expres-
sion was observed in normothermic controls.
The analyzed HSP27, HSP70, and HSP90 expression pro-
files indicate prolonged intracellular repair mechanisms in a 
minor population of the colon cancer cells to survive the cellular 
stress exerted by hyperthermia and particularly cytostatic treat-
ment. However, it should be taken into account that the investi-
gated tumor cells have been kept under optimized conditions 
including fresh RPMI medium with fetal calf serum and con-
stantly CO2 atmosphere following the hyperthermic chemo-
therapy. Under clinical circumstances, hypoxia and diminished 
blood supply in the abdomen may aggravate the HIPEC-
induced intracellular stress with even more prolonged and vigor-
ous HSP-mediated repair mechanisms in the tumor cells. Thus, 
remaining single or aggregated tumor cells that are detached 
from peritoneal surface metastases and are incompletely affected 
from a HIPEC procedure may survive through HSPs that cir-
cumvent tumor cell apoptosis under such circumstances.
To protect cells from such damage and apoptosis, HSPs 
interact with several survival and antiapoptotic pathways 
allowing the cell to deal with potentially lethal conditions.16 
HSP27 has been shown to interact and inhibit components of 
both extrinsic and intrinsic apoptotic pathways.32 The extrinsic 
apoptotic pathway is blocked by the inhibition of tBid (trun-
cated BID), a membrane-targeted death ligand that induces 
release of cytochrome c from the mitochondria. Moreover, 
binding of HSP27 to DAXX (death domain–associated pro-
tein) prevents transmission of the extrinsic signal to proapop-
totic Bcl-2.33 In addition, HSP27 binds to cytochrome c itself 
thus suppressing the progress of apoptosis through inhibition 
of the interaction with Apaf-1 (apoptotic peptidase–activating 
factor 1) and the following activation of caspase 9 and assembly 
of the apoptosome.34,35 It also disables the release of Smac/
Diablo and their inhibition of IAPs (inhibitors of apoptosis).36 
Moreover, HSP27 inhibits apoptosis by regulating upstream 
signaling pathways. Survival factors, such as the platelet-
derived growth factor, inhibit apoptosis by activating the PI3K/
Akt (phosphatidylinositol 3-kinase/protein kinase B) pathway. 
Akt targets multiple proteins of apoptotic signaling pathways, 
including Bad (Bcl-2–associated agonist of cell death) and cas-
pase-9, and HSP27 has been shown to bind Akt and cause its 
activation in stressed cells.32,37
HSP70 also enhances the ability of cells to suppress apop-
tosis under potentially lethal conditions. The extrinsic path-
way of apoptosis is blocked twice by the interaction of HSP70 
with ASK (apoptosis signal-regulating kinase) and JNK (c-Jun 
N-terminal kinase).38 It inhibits the stress-induced dephos-
phorylation of JNK and abides the level of inactive JNK. JNK 
is involved in the regulation of various proteins within apop-
totic signaling pathways, eg, the protooncogene c-Myc, the 
tumor suppressor p53, and Bcl2, all involved in permeabiliza-
tion of the mitochondrial membrane.39,40 Moreover, the cleav-
age of Bid to tBid and the following release of cytochrome c 
factors into the cytoplasm are inhibited by HSP70.41 In addi-
tion, by blockade of Apaf-1, HSP70 inhibits formation of the 
apoptosome.42
Similar to HSP27 and HSP70, HSP90 also exerts antia-
poptotic functions to support cellular survival mechanisms. Just 
as HSP70, HSP90 directly interacts with Apaf-1 and inhibits 
the formation of a functional apoptosome and the recruitment 
and activation of procaspase 9.43 HSP90 also interferes with 
the death receptor/nuclear factor κB (NF-κB) signaling cas-
cade by binding to RIP (receptor-interacting protein) which 
interacts with the death receptors of the TNFR (tumor necro-
sis factor receptor) family. This interaction provokes an 
increased activation of IKK (IκB kinase complex) and thus 
inactivation of IκB (inhibitor of NF-κB). Consequently, 
NF-κB can serve as an active transcription factor for several 
antiapoptotic target proteins such as Bcl-xL.44
Interestingly, hyperthermic chemotherapy resembling 
HIPEC-like conditions in the clinic induced expression of 
antiapoptotic Bcl-xL as shown in the investigated colon cancer 
cells and confirmed in peritoneal metastatic tumor tissues from 
patients with colorectal cancer undergoing HIPEC procedures. 
Moreover, an increased “chemoresistance” was observed in 
colon cancer cells treated with hyperthermic chemotherapy 
compared with normothermic incubation with 5-FU, MMC, 
and OXA. Remarkably, proliferation markers, PCNA and 
Ki-67, were induced in these tumor cells exposed to chemo-
therapy which was in case of PCNA confirmed in peritoneal 
tumor tissues after clinical HIPEC procedures. The results 
indicate that a minor population of incompletely damaged and 
robust tumor cells was responsible for the observed increase in 
expression of proliferation markers and that this phenomenon 
was attributed to a rebound effect during first days after hyper-
thermic chemotherapy. In addition, results from MTS assays 
were in line with those from tumor cell proliferation markers 
and demonstrated increased tumor cell viability in samples 
exposed to hyperthermic chemotherapy compared with nor-
mothermic treatment. Consequently, these tumor cells survived 
the hyperthermic and chemotoxic stress.
Based on their interference with apoptotic pathways, HSPs 
have become an interesting target for inhibitory strategies in 
cancer therapy. Many potential inhibitors of particularly 
HSP90 have been tested for cancer therapy, and currently, 
HSP90 inhibitors are being evaluated in numerous clinical tri-
als.45 Next to STA-9090, AUY922 is in development, and the 
combination of AUY922 with 5-FU and OXA has been 
described to show a synergistic antiproliferative effect in gas-
tric cancer.45,46 As HSP90 inhibition has been demonstrated 
to induce the expression of HSP70, dual targeting of HSP70 
and HSP90 might be beneficial to successfully inhibit HSP-
dependent antiapoptotic mechanisms.47 Different small-mol-
ecule HSP70 inhibitors such as VER155008 and 
2-phenylethynesulfonamide have already been proven to 
enhance the cytotoxicity of HSP90 inhibitors.47–50 For target-
ing HSP27, 2 small-molecule inhibitors, quercetin and RP101, 
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are under development. Similar to AUY922, quercetin poten-
tiates the effects of many first-line chemotherapeutics includ-
ing doxorubicin, cisplatin, gemcitabine, and 5-FU.51–53 
Interestingly, the herein presented cell viability data from HSP 
inhibition assays, using a combination of HSP90 (17-AAG) 
and HSP70 (VER155008) inhibitors, indeed demonstrated 
significantly reduced viability in our colon cancer cells previ-
ously exposed to hyperthermic chemotherapy, suggesting a 
beneficial effect of HSP inhibition after HIPEC therapy.
In summary, our findings from in vitro mechanistic studies 
as well as investigation of peritoneal colon cancer metastases 
after a HIPEC procedure indicate that induction of HSP27, 
HSP70, and HSP90 expression through hyperthermic and 
cytostatic stress in colon cancer cells actively inhibits apopto-
sis-inducing effects during and after the exposure to HIPEC-
induced stress. In addition, cancer cells that were able to survive 
the hyperthermic and chemotoxic damage demonstrated 
increased cell viability and proliferation.
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